Meral K. El Ramahi, MD MeralElRamahiMD

3 years 6 months ago

2021 GRAPPA STRONG recs: *⃣Axial PsA/arthritis, biologic-naive or IR: TNFi, IL17i, JAKi *⃣Peripheral arthritis biologic-IR: above + IL23i *⃣Peripheral arthritis DMARD-IR: above + IL12/23i *⃣Peripheral arthritis DMARD-naive: above + PDE4i + csDMARD OP0229 #EULAR2021 @RheumNow https://t.co/Z2Nv073yoU

Robert B Chao, MD doctorRBC

3 years 6 months ago

Deucravacitinib (TYK2i) - phase II trial for PsA ⭐️ACR20, 50, 70 response ⭐️HAQ-DI response ⭐️LEI/SPARCC response ⭐️MDA response Abs#OP0227 #EULAR2021 @RheumNow

2021 GRAPPA Treatment Guidelines for Adult PsO & PsA Patients: Dr. Rachel Tate

3 years 6 months ago

Richard Conway RichardPAConway

3 years 6 months ago

Dr Deodhar on upadacitinib in axial PsA. Appears to be effective in combined analysis of SELECT-PsA 1 and 2. @RheumNow #EULAR2021 Abstr#0233 https://t.co/fBMWVb3oBd

Janet Pope Janetbirdope

3 years 6 months ago

Cool special effects in #EULAR2021 symposium: A practical guide to the use of JAKi in RA & SpA. Beamed in & out of talk like #StarTrek @eular_org @RheumNow https://t.co/y4qToeFKE7

When to use a JAK inhibitor in RA: Dr. Janet Pope

Janet Pope, MD, MPH, FRCPC

3 years 6 months ago

EULAR 2021 - Day 2 Podcasts

Jack Cush, MD

3 years 6 months ago

Check out this compilation of our EULAR 2021 Day 2 broadcasts below. You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com Listen by Clicking below: 1.…

Janet Pope Janetbirdope

3 years 6 months ago

After 1st JAKi in RA would you use a 2nd #Jaki? @eular_org

Janet Pope Janetbirdope

3 years 6 months ago

JAKi has better retention than a bDMARD in RA! Single site study of RA pts prescribed advanced therapy in 320 Rxs in 215 pts JAKi lasted longer adjusting for age, sex, RA duration & line of therpy & 1st line Rx POS0205 #EULAR2021 @RheumNow https://t.co/4m2RXBkTDr